Addus HomeCare (NASDAQ:ADUS) Stock: Insider R Dirk Allison Sells 98,958 Shares

Addus HomeCare Corporation (NASDAQ:ADUS) CEO R. Allison sold 98,958 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $123.27, for a total transaction of $12,198,552.66. Following the completion of the sale, the chief executive officer owned 183,150 shares in the company, valued at $22,576,900.50. This represents a 35.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Addus HomeCare Price Performance

Addus HomeCare stock opened at $125.49 on Thursday. Addus HomeCare Corporation has a 52-week low of $87.95 and a 52-week high of $131.59. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average is $118.19 and its 200 day moving average is $107.10. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 1.66 and a beta of 0.75.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Addus HomeCare had a net margin of 7.39% and a return on equity of 10.22%. The business had revenue of $387.74 million during the quarter, compared to analysts’ expectations of $388.72 million. During the same period last year, the company posted $1.56 EPS. The business’s revenue was up 7.0% on a year-over-year basis. Sell-side analysts forecast that Addus HomeCare Corporation will post 6.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ADUS shares. Citigroup cut Addus HomeCare from a “market outperform” rating to a “neutral” rating in a research note on Monday, September 14th. Raymond James Financial set a $137.00 price objective on Addus HomeCare in a research note on Monday, September 28th. Wall Street Zen upgraded Addus HomeCare from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. UBS Group lifted their target price on Addus HomeCare from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Weiss Ratings raised Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.70.

Hedge Funds Weigh In On Addus HomeCare

Large investors have recently made changes to their positions in the company. Hsbc Holdings PLC raised its position in Addus HomeCare by 73.3% in the 2nd quarter. Hsbc Holdings PLC now owns 24,463 shares of the company’s stock worth $2,446,000 after purchasing an additional 10,350 shares during the period. Summit Creek Advisors LLC purchased a new position in shares of Addus HomeCare during the second quarter valued at approximately $8,552,000. Globeflex Capital L P purchased a new position in shares of Addus HomeCare during the second quarter valued at approximately $1,635,000. Bank of America Corp DE boosted its position in shares of Addus HomeCare by 11.3% during the first quarter. Bank of America Corp DE now owns 323,037 shares of the company’s stock valued at $30,252,000 after buying an additional 32,714 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Addus HomeCare during the second quarter valued at approximately $901,000. 95.35% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Addus HomeCare

Investors following ADUS have been watching these stories:

• Positive Sentiment: TD Cowen raised its price target to $145 and reiterated a Buy rating; Wall Street Zen also upgraded the stock to Strong Buy. The company’s latest reported quarterly EPS of $1.83 topped the $1.79 consensus, while revenue grew 7% year over year, though it narrowly missed estimates.
• Neutral Sentiment: Addus plans to participate in the 2026 Stephens Annual Investment Conference. The announcement offers investor access but provides no new operating or financial guidance. Article: Addus HomeCare to Participate in 2026 Stephens Annual Investment Conference
• Neutral Sentiment: A report claims short interest was zero shares, despite describing it as a large increase. The conflicting wording makes the short-interest update difficult to interpret.

About Addus HomeCare

Addus HomeCare Corporation provides home-based care services to older adults and people with disabilities. Its services are designed to help clients receive care at home and in other community-based settings. The company operates through personal care, hospice and home health services. Personal care includes assistance with daily activities; hospice provides end-of-life care and support; and home health offers skilled nursing and therapy services. Founded in 1979, Addus serves communities across multiple states.